MARLBOROUGH,
Mass., June
15, 2017 /PRNewswire/
-- Hologic, Inc. (Nasdaq: HOLX) announced
today that the U.S. Food and Drug Administration (FDA) has granted
an expanded clearance for Cynosure's non-invasive body contouring
product, SculpSure, to treat the back and inner and outer thighs.
The SculpSure treatment is already FDA-cleared for treatment of the
abdomen and love handles (flanks).
SculpSure is a clinically proven, non-surgical body contouring
(lipolysis) treatment designed to permanently eliminate fat cells
in problem areas. Developed by Cynosure, a world leader in medical
aesthetics and division of Hologic, SculpSure utilizes a selective
wavelength laser that precisely targets fat cells under the skin.
The laser raises the temperature of body fat to disrupt and destroy
these cells, which are naturally eliminated over time and do not
return. Patients are able to achieve desired results – without
downtime or surgery – through customized treatment plans, each
lasting only 25 minutes.
"The approval of SculpSure to treat back fat and the inner and
outer thighs is a direct response to the growing needs of our
consumers, who are looking to achieve a slimmer appearance and
enhance the body they work hard to maintain," said Michael Davin, Divisional President of Cynosure
at Hologic. "Cynosure is a leader in medical aesthetics and pioneer
in light-based fat reduction, and we expect the addition of three
known body problem areas to SculpSure's already advanced, versatile
treatment to further drive demand and pave the way for future
innovations."
To learn more about SculpSure, please visit
www.SculpSure.com.
About Hologic, Inc.
Hologic, Inc. is an innovative
medical technology company primarily focused on improving women's
health and well-being through early detection and treatment.
For more information on Hologic, visit
www.hologic.com.
Hologic, The Science of Sure and SculpSure are registered
trademarks of Hologic, Inc. in the United
States and/or other countries.
Forward-Looking Statements
This news release may
contain forward-looking information that involves risks and
uncertainties, including statements about the use of Hologic
products. There can be no assurance these products will achieve the
benefits described herein or that such benefits will be replicated
in any particular manner with respect to an individual patient, as
the actual effect of the use of the products can only be determined
on a case-by-case basis. In addition, there can be no assurance
that these products will be commercially successful or achieve any
expected level of sales. Hologic expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
such statements presented herein to reflect any change in
expectations or any change in events, conditions or circumstances
on which any such data or statements are based.
Media Contact
Jane
Mazur
508.263.8764 (direct)
585.355.5978
(mobile)
jane.mazur@hologic.com
Investor Contact
Michael
Watts
858.410.8588
michael.watts@hologic.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/hologic-receives-expanded-fda-510k-clearance-to-market-cynosures-sculpsure-for-non-invasive-body-contouring-lipolysis-of-back-inner-and-outer-thighs-300474354.html
SOURCE Hologic, Inc.